SUMMARY -Glioblastoma multiforme (GBM) is caused by the central nervous system-derived glial cells, and represents the most common (50%-60%) form of primary brain tumors. Th e aim of this study was to investigate the in vitro eff ects of selenium on human GBM cells. In the present study, GMS-10 and DBTRG-05MG human GBM cell lines were used as a model to examine selenium entering the cell, cell proliferation, cytotoxicity, DNA fragmentation and Ki-67 protein expression in selenomethionine treated and non-treated groups. Seleno-L-methionine (SeMet) as the organic source of selenium exerted eff ects on cell proliferation and cytotoxicity, as assessed with WST-1 and lactate dehydrogenase (LDH) tests, respectively. Apoptosis was assessed by DNA fragmentation with an enzyme-linked immunosorbent assay. Ki-67 protein expression was determined by Western blotting, while selenium measurements were performed in the supernatants and lysates by using Graphite Furnace Atomic Absorption Spectrometry. Th is is the fi rst study to examine the eff ects of SeMet on cell proliferation and death in GMS-10 and DBTRG-05MG cells. Both GBM cell lines responded to SeMet in a dose-and time-dependent manner. WST-1 test showed that low-dose SeMet treatment (50 and 100 μM) increased cell proliferation. Analysis of intracellular SeMet levels by using AAS showed results consistent with viability and cytotoxicity tests. SeMet treatment for 72 h caused increased DNA fragmentation in both cell lines. In conclusion, our results suggest that SeMet induces cell death at high doses, while increasing cell proliferation at low doses. In the view of the data obtained in this investigation, further studies focusing on the possibility of using SeMet against different types of GBM and in combination with prospect synergic compounds are considered to be worthwhile.
Introduction
Selenium is an essential trace element and an extraordinary element 1, 2 . Its own codon enables its incorporation into proteins as selenocysteine 3 . Selenium functions in antioxidant mechanisms, immune systems, detoxifi cation mechanisms, infl ammation, male fertility, and also exerts anti-cancer eff ects 4 . Several studies have shown that certain selenium compounds, such as selenite and seleno-L-methionine, have roles as chemopreventive agents in diff erent cancers, including prostate, melanoma, lung, esophageal and gastriccardia cancers [5] [6] [7] . Glioblastoma multiforme (GBM) is the most aggressive brain cancer due to its capacity of rapid inva-sion and its strong resistance to therapy 8 . Median survival is 10 to 12 months 9 . Some patients can live up to 14 months 10, 11 . Several reports have shown that treatment with antioxidants is benefi cial in preventing tumor growth. Recently, temozolomide, bevacizumab, and other alkylating agents are used in the treatment of glioblastoma, but drug resistance is the most important problem 12, 13 . To overcome this therapeutic challenge, new approaches involving a combination of anti-cancer drug and antioxidant treatment have been developed 14 . Previous studies have investigated, both in vitro and in vivo, the preventive and therapeutic eff ects of selenium on diff erent cancers, including prostate 5, 15 , lung 16 , colon 17 , breast 7 , melanoma 18 , and various brain tumors [19] [20] [21] [22] . Inorganic forms of selenium, including sodium selenite and sodium selenate, have been used in these studies.
To our knowledge, seleno-L-methionine (SeMet), the organic form of selenium, has not been tested in any study. We hypothesized that SeMet would be effective in controlling cell proliferation and apoptotic cell death. Here, we investigated, on two diff erent human GBM cell lines, the eff ects of SeMet on proliferation, cytotoxicity, and Ki-67 protein expression. In addition, correlation with the amount of selenium entering the cell (following treatment with diff erent doses of SeMet) was also evaluated.
Materials and methods

Test chemicals
Seleno-L-methionine (MW 196.11 g/mol, CAS Number 3211-76-5; Sigma, USA) was dissolved in distilled water. Th en, the solution was fi ltered and diluted as required. All dilutions were carried out using the medium. All treatments were carried out at fi nal concentrations of 50, 100, 500 and 1000 μM.
Cell culture
Adherent human GBM cells, GMS-10 and DBTRG-05MG, were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ). GMS-10 cells were cultured in Dulbecco's Modifi ed Eagle's Medium (DMEM, D6046; Sigma; USA), while DBTRG-05MG cells were cultured in RPMI 1640 (Hyclone, Th ermo Scientifi c; USA) supplemented with 10% fetal calf serum (Biological Industries, Israel), 1% L-glutamine (G7513; Sigma; USA), and 1% penicillin-streptomycin (P4333; Sigma; USA) at 37 °C in 95% air and 5% CO 2 incubator 23, 24 . Cells were trypsinized at a split ratio of 1:2 or 1:3.
SeMet treatment
Both cell lines were treated with diff erent concentrations of SeMet (50-1000 μM) for 24, 48 and 72 h. Afterwards, cell survival was assessed qualitatively by light microscopy.
Cell viability assay
Th e inhibition of cell growth was determined by [2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium] kit (WST-1 05 015 944 001, Roche). All GBM cells were seeded on 96-well plates (1x10 4 cells/well) and treated with 50, 100, 500 and 1000 μM SeMet for 24, 48 and 72 h. Th en, 10 μL of WST-1 stock solution was added to each well. Cells were incubated at 37 °C for 0.5-4 h. After incubation, cell viability was assayed by measuring the absorbance at 440 nm on a microplate reader (Bio-Tek Instruments, Inc., USA). Th e results were expressed as mean optical density (OD) of experimental groups (n=5) vs. control (non-treated cells). Th e mean OD of the control group was set to represent 100% cell viability 25 .
Cell death assay
Cell death was analyzed by using lactate dehydrogenase (LDH) assay (LDH 11 644 793 001, Roche). Quantifying the amount of LDH in the medium from dead cells and dividing the result by the total amount of LDH in the medium and cell lysate in the sample calculated the cell cytotoxicity percentage. Cell cytotoxicity results were expressed as the percentage of LDH released. All GBM cells were seeded on 96-well plates (1x10 4 cells/well) and treated with 50, 100, 500 and 1000 μM SeMet for 24, 48 and 72 h. Th en, a 10-μL lysis solution was added to the wells to achieve maximal release in maximal group cells. Cells were incubated at 37 °C for 2 h for lysis. After incubation, LDH working solution was added to each well (supernatants without cell) and LDH released from the medium was detected by measuring absorbance at 490 nm using a microplate reader (Bio-Tek Instruments, Inc., USA) 26 .
Cell death ELISA
Apoptosis was assessed by DNA fragmentation with an enzyme-linked immunosorbent assay (Cell Death ELISA Plus Kit 11774425001, Roche). Briefl y, 1x10 4 cells/well were seeded on 96-well plates and treated with 50, 100, 500, and 1000 μM SeMet for 24, 48 and 72 h. Th e plate was centrifuged at 600 g at 4 °C for 10 minutes and then the supernatants were removed. Th e cell pellet containing apoptotic bodies was lysed with 0.2 mL of a lysis buff er (cell death ELISA Plus, Roche) and incubated for 30 minutes at room temperature. Cell lysate solutions (20 μL) were placed in duplicate into the wells of the streptavidin-coated microplate, to which 80 μL of the immunoreagent containing a mixture of anti-histone-biotin and anti-DNA-POD was added. Th e plate was covered with an adhesive cover foil and incubated for 2 h at 25 °C in a shaking incubator at 300 rpm. During the incubation period, the anti-histone antibody binds to the histone component of the nucleosomes and simultaneously captures the immunocomplex to the streptavidincoated microplate via its biotinylation. At the same time, the anti-DNA-POD antibody reacts with the DNA component of the nucleosomes. Th e unbound antibodies were washed with the incubation buff er. Th e amount of nucleosomes retained by the POD in the immunocomplex, corresponding to the extent of apoptosis was quantitatively determined photometrically with ABTS (2,2'-azinobis-3-ethyl-benzothiazoline-6-sulfonic acid) as substrate, using a microplate reader at a wavelength of 405 nm and reference wavelength of 490 nm. Th e enrichment of mono-and oligonucleosomes in the cytoplasm of the apoptotic cells is due to the fact that DNA degradation occurs several hours before the plasma membrane breakdown. Quantifying the average OD from dead cells and dividing the result by that of average control cells yielded the enrichment factor.
Selenium measurement
Cell lysates and supernatants, which were obtained from the cell lines after incubation, were collected for selenium measurements, which were done by using Graphite Furnace Atomic Absorption Spectrometry (GFAAS). After incubation, cell media were collected and transferred to sterile falcons and the cells were scraped with a cell scraper. Th e 1000-ppm selenium standard (Titrisol Merck) solution was diluted to 1 ppm in 0.1 M HCl and then prepared to buff er stock concentrations in the range of 25-800 μg/L. All these buff er stock solutions were diluted to working concentrations in the range of 5-200 μg/L with the matrix modifi er which was composed of 190 mg palladium nitrate and 60 mg magnesium nitrate, 200 μL triton X-100 dissolved in 100 mL 0.1 M HCl. Before analysis, cell lysates were diluted (1:100) with the matrix modifi er. Th e matrix modifi er was used as blank. All standards and samples were then placed in the auto sampler vial for GFAAS analysis. Th e sample injection volume was 20 μL. Selenium was detected at 196 nm [27] [28] [29] .
Western blot
Following SeMet incubation, the cell lines were lysed in lysis buff er (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 20 mM MgCl 2 , 1% Nonidet P-40, 0.1% sodium dodecyl sulfate (SDS), and 1 mM PMSF, aprotinin (1 μg/mL) and leupeptin (1 μg/mL)). After the cells had been lysed, the protein concentrations were measured using a BCA protein assay kit (Pierce BCA Protein Assay Kit 23225, Th ermo Scientifi c). Equal amounts of total cellular protein samples (15 μg) were separated on a 6% SDS-polyacrylamide gel at 100 V and transferred onto a PVDF membrane for 2 h at 200 mA (Atto). Th e membranes were incubated with 5% non-fat dry milk and 3% BSA, specifi c primary antibodies at 1:250 and 1:500 directed to either Ki-67 (Santa Cruz, Cat No. sc-7844) and calnexin (Santa Cruz, Cat No. sc-6465) overnight at 4 °C, followed by incubation with appropriate HRP conjugated secondary antibodies (donkey anti-goat IgGHorseradish Peroxidase Conjugated Affi nity Purifi ed Antibody, Santa Cruz, Cat No. sc-2020) at 1:1000 dilution in PBS for 1 h at room temperature and subsequent chemiluminescent detection using standard quality x-ray fi lms 30 .
Statistical analysis
All data were expressed as mean ± SD and corresponded to the results of at least three independent experiments. Th e average of fi ve wells was taken for each parameter. Th e cells treated with the medium served as control (100% viable) and the remaining samples were expressed as viability percentage decrease or increase as compared with the control. Kolmogorov-Smirnov test was used to assess whether the variables fi tted normal distribution and showed a nonnormal distribution. One-way ANOVA was used to analyze diff erences among these non-normally distributed groups. Pearson's correlation test was used to determine correlation among experimental parameters. P values <0.05 were considered as statistically signifi cant. SPSS v.19.0 (Chicago, IL, USA) was used for statistical analysis.
Results
SeMet treatment suppresses GBM cell proliferation in a dose-and time-dependent manner
Two human GBM cell lines were treated with increasing concentrations of SeMet for 24, 48 and 72 h. Th en, cell viability was assessed by the WST-1 assay. As shown in Figure 1A and B, SeMet stimulated proliferation of cell lines in a dose-dependent manner. For the GMS-10 cell line, low doses (50 μM and 100 μM) were found to induce proliferation at 24 h (Fig. 1A) . We did not fi nd signifi cant diff erence between the SeMet treated two cell lines for 24 h, but a signifi cant diff erence (p<0.05) was found for 48 h and 72 h (Fig.  1) . After 72-h SeMet treatment, the IC 50 values were 500±200 μM for GMS-10 and 500±100 μM for DB-TRG-05MG.
SeMet treatment induces apoptosis in GBM cells
Th e LDH assay showed that high dose SeMet treatment (500 μM and 1000 μM) induced cell death at 24 h. After 72 h, 50 μM SeMet resulted in 2.08± 0.45% increase, 100 μM in 13.26±0.76% increase, 500 μM in 35.52±1.37% increase and 1000 μM in 50.10± 2.29% increase in cell death for the DBTRG-05MG cell line compared with control. For the GMS-10 cell line, 50 μM SeMet resulted in no death, whereas 100 μM resulted in 3.99±0.65%, 500 μM in 10.0±0.89% and 1000 μM in 20.96±1.90% increase in cell death compared with control. Furthermore, we found negative correlation between the results of the LDH assay and WST-1 assay. Th e results of the LDH assay correlated negatively with the results of the WST-1 assay. Pearson's correlation test results and the related r and p values are indicated in Table 1 .
DNA fragmentation: apoptotic eff ects of SeMet
DNA fragmentation analysis showed that SeMet induced apoptosis in both GBM cell lines after 72-h incubation. To quantify and further support the fi nding that SeMet treatment causes cell death in GBM cells, we performed cell death detection by ELISA. Compared with controls, treatment of GMS-10 cells with SeMet at 500 μM and 1000 μM concentrations resulted in 2.94-and 4.03-fold increase in the induction of apoptosis, respectively.
GMS-10 and DBTRG-05MG cells were treated with diff erent doses of SeMet and cell proliferation was assayed at diff erent time points: (A) WST-1 assay of cell proliferation of GMS-10 cells treated with four diff erent doses of SeMet using 24 h, 48 h, and 72 h incubation times; (B) WST-1 assay of cell proliferation of DBTRG-05MG cells treated with four diff erent doses of SeMet. Th e results were expressed as the mean optical density (OD) of experimental groups (n=5) vs. control (non-treated cells). Th e mean OD of the control group was set to represent 100% cell viability. Data represent the mean of three independent experiments compared with control group (**p<0.01, *p<0.05). 
Fig. 1. Seleno-L-methionine (SeMet) suppresses glioblastoma multiforme (GBM) cell proliferation in a doseand time-dependent manner.
Fig. 2. Seleno-L-methionine (SeMet) triggers apoptotic cell death in a dose-dependent manner.
Analysis of intracellular and extracellular selenium levels
Selenium uptake of the cells was assessed by measuring selenium levels in the supernatants (extracellular) and lysates (intracellular) by GFAAS. At each dose, SeMet uptake was highest at 48 h. However, there was no signifi cant diff erence compared with the control group.
Ki-67 protein expression
Th e SDS-PAGE and Western blotting determined protein levels of Ki-67 following SeMet treatment. Ki-67 band images were shown in the GMS-10 cells at 24 h (UVP BioImaging System, UK).
Discussion and Conclusions
Th e 'magic bullet theory' proposed by Paul Ehrlich a century ago still remains valid in the treatment of cancer. According to Ehrlich, the magic bullet is a compound that targets a single certain oncoprotein in a highly specifi c fashion and does not damage healthy cells 31 . Today, current research is focused on targeted molecular treatment alternatives. Th is situation is valid for GBM. Th e development of drug resistance is a common condition in GBM. Th e most important problem with drugs is associated with those that cannot pass the blood-brain barrier 32 . Selenium can cross the blood-brain barrier and selenoprotein P is expressed in the brain 33 . Th e chemical form of selenium 
Fig. 3. (A) Seleno-L-methionine (SeMet) levels in GMS-10 (a) and DBTRG-05MG (b) cell lysates at 24 h, 48 h and 72 h (**p<0.01, *p<0.05); (B) SeMet levels in GMS-10 (a) and DBTRG-05MG (b) cell supernatants at 24 h, 48 h and 72 h (**p<0.01, *p<0.05).
is signifi cant. Inorganic forms of selenium are more toxic than organic forms of selenium. Selenomethionine is an organic form of selenium possessing anticancer properties. First data came from the Nutritional Prevention of Cancer (NPC) study, which indicated that selenium compounds have chemopreventive properties, but then the SELECT study has reported debate on the issue 34 . Th e GMS-10 glioblastoma cells used are cancerous brain cells derived from a GBM patient 23 . DBTRG-05MG cells were obtained from a GBM patient having undergone surgery after chemotherapy and radiotherapy 24 . GMS-10 cells are null for p53 gene, but DBTRG-05MG cells have not lost their heterozygosity for the p53 23, 24 . After 24-h SeMet treatment, two tumor cells were aff ected diff erently. Th e 50 μM and 100 μM SeMet treatment of GMS-10 cells for 24 h unexpectedly exerted proliferative activity, but under these conditions DBTRG-05MG cells were not affected. Interesting enough, in a way contrary to the nature of antioxidants, SeMet did not fi ght the cancer cells at 50-μM and 100-μM doses. Similarly, Sayin et al. demonstrated that antioxidants accelerated lung cancer progression in mice 35 . In this study, this diff erence may have resulted from diff erences in p53 status.
In this investigation, SeMet treatment decreased cell proliferation and showed cytotoxicity in a doseand incubation period-dependent manner in both cell lines (except for 50 μM and 100 μM SeMet treatment of GMS-10 cells for 24 h). Furthermore, these parameters correlated to a large extent with the level of SeMet having entered the cells.
Previous studies have shown that SeMet aff ected diff erent cell types at diff erent concentrations and incubation times. Redman et al. 36 found that IC 50 levels of 45 μM SeMet for MCF-7/S cells, 50 μM SeMet for UACC-375 cells, 130 μM SeMet for HT-29 cells, 40 μM SeMet for DU-145 cells, 65 μM SeMet for A549 cells and 1 mM SeMet for fi broblast cells inhibited 50% of the growth. Suzuki et al. 37 applied SeMet in the range of 10-1000 μM to HSC-3, HSC-4, A549 and MCF-7. In the present study, the IC 50 values for SeMet were 500±200 μM for GMS-10 and 500±100 μM for DBTRG-05MG. Given that GBM is the most aggressive and resistant primary brain tumor, such higher values are expected for GBM. Th e amount of selenium daily intake for normal people is 55 to 70 mg/day. Th e body can tolerate maximum selenium level of 400 mg/day 38 . Th e doses used in this study were slightly higher than the recommended daily allowance, but they were still within the tolerable range.
In reviewing the literature, Zhu et al. 21 showed that selenite (0.01-100 μM) inhibited cell growth on C6 20 showed that selenite induced apoptosis on A172 and T98 human glioblastoma cells. In this study, we found that after 24-h and 48-h SeMet treatment, DB-TRG-05MG cell death increased signifi cantly at high doses (500 and 1000 μM), but GMS-10 cells were not killed by SeMet after 24 h, whereas they were killed at the 500 μM dose signifi cantly after 48-h incubation. After 72-h SeMet incubation, DBTRG-05MG cell death increased at 100, 500 and 1000 μM doses signifi cantly, and GMS-10 cells were killed by SeMet on the same doses but not signifi cantly. As a result of the WST-1 and LDH assays, negative correlation was found between the proliferation and cytotoxicity fi ndings and these parameters correlated to a large extent with the level of SeMet entering the cells. Th e highest SeMet level in both cell lines was measured after 48-h treatment. Th ese fi ndings correspond to the results of proliferation assays and suggest that SeMet cytotoxicity appears to be explained in part by the induction of apoptosis. Interestingly, we observed a signifi cant increase in apoptosis in both cell lines. Th is condition may be related to the cell p53 status and the development of SeMet resistance in GMS-10 cells. Seo et al. 39 showed that SeMet could activate the p53 protein by a redox mechanism and SeMet diff erentially aff ected cells wild type or null for p53 genes. In the view of such information, our data must be supported by new experiments such as siRNA transfection and apoptosis assays.
Ki-67 is a well-known proliferation marker, such as cyclin E, cyclin D and proliferating cell nuclear antigen (PCNA) 36 . Previous studies evaluated Ki-67 protein levels by immunohistochemistry, ELISA or Western blotting [40] [41] [42] . Jin et al. 43 showed that Ki-67 was associated with cell growth and regulating proliferation in GBM. In the present study, Ki-67 band images were determined on GMS-10 cells at 24 h and also at 48 h, but at 48 h and 72 h reproducible band images were not achieved. Th ese fi ndings suggest that Ki-67 is one of the examples of the proliferation signature in GBM, but further studies are needed to evaluate Ki-67 protein levels with other components of cellular proliferation signaling.
Th is is the fi rst study to examine SeMet eff ects on cell growth and death in GMS-10 and DBTRG-05MG cells. Our fi ndings indicate that SeMet induces cell death at high doses, but increases cell proliferation at low doses. Altogether, SeMet appears to be a promising agent for GBM therapy, and the therapeutic potential of SeMet, alone or in combination with conventional treatment agents, warrants additional studies.
